Colossal Biosciences, a Dallas, TX-based de-extinction company, raised $150M in Series B funding.
The round was led by United States Innovative Technology Fund, with participation from Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, and Jazz Ventures.
The company intends to use the funds to continue to advance genetic engineering and pioneer new software, wetware and hardware solutions, all of which have applications to de-extinction, conservation and human healthcare.
Founded by technology and software entrepreneur Ben Lamm and George Church, Colossal creates technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. As part of its Series B, the company has also announced the launch of its Avian Genomics Group, which will pursue the de-extinction of the iconic Dodo, a bird species that was wiped out of its native ecosystem, Mauritius, as a direct result of human settlement and ecosystem competition in 1662.
The Woolly Mammoth de-extinction team now includes over 40 talented scientists and three laboratories to innovate across computational biology, cell and genome engineering, stem cell biology, embryology, protein engineering and assisted reproductive technologies. The Colossal Thylacine team consists of 30 dedicated scientists.
FinSMEs
31/01/2023